Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?

Br J Haematol. 2023 Jan;200(1):e6-e7. doi: 10.1111/bjh.18505. Epub 2022 Oct 25.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Receptors, Antigen
  • Receptors, Antigen, T-Cell / genetics
  • Standard of Care*

Substances

  • Receptors, Antigen
  • Receptors, Antigen, T-Cell